Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

导出原文传递

翻译打印收藏纠错

作者： Molife,L.R. ^[1] ; Rudman,S.M. ^[2] ; Alam,S. ^[3] ; Tan,D.S.-W. ^[4] ; Kristeleit,H. ^[5] ; Middleton,G. ^[6] ; Propper,D. ^[7] ; Bent,L. ; Stopfer,P. ; Uttenreuther-Fischer,M. ; Wallenstein,G. ; DeBono,J. ; Spicer,J.

作者单位： Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany ^[1] Drug Development Unit, Royal Marsden Hospital, Institute of Cancer, Research Downs Road, Sutton ^[2] Department of Oncology, Guy's and St. Thomas' National Health Service (NHS) Foundation Trust ^[3] St. Luke's Cancer Center, Royal Surrey County Hospital, Guildford Surrey, United Kingdom ^[4] Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim, Germany ^[5] Centre for Experimental Cancer Medicine, Barts Cancer Institute, London, United Kingdom ^[6] Boehringer Ingelheim Ltd., Bracknell, United Kingdom ^[7]

关键词 Antitumor activity Cardiac safety ErbB family blocker Pharmacokinetics Solid tumors

发布时间 2014-04-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交